EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSMLUG00000027015
Gene Symbol: BDKRB2
2 Cross references
356 Possible Orthologues:

Butyrylcholinesterase

Ensembl ID : ENSMLUG00000003979
Gene Symbol: BCHE
2 Cross references
130 Possible Orthologues:

Cgmp-Specific 3',5'-Cyclic Phosphodiesterase

Ensembl ID : ENSMLUG00000012814
Gene Symbol: LOC102430691
3 Cross references
213 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSMLUG00000014787
Gene Symbol: CALCRL
2 Cross references
147 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSMLUG00000009054
Gene Symbol: CASR
4 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSMLUG00000007796
Gene Symbol: CACNA2D1
2 Cross references
285 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSMLUG00000013340
Gene Symbol: CACNA2D3
4 Cross references
307 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSMLUG00000002221
Gene Symbol: CACNA2D4
2 Cross references
317 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSMLUG00000012550
Gene Symbol: CACNB1
2 Cross references
209 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSMLUG00000001818
Gene Symbol: CACNB2
2 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSMLUG00000010986
Gene Symbol: CACNB3
2 Cross references
275 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSMLUG00000003465
Gene Symbol: CACNB4
2 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).